In vitro screening of soil bacteria for inhibiting phytopathogenic fungi

At present, the greatest interest resides with the development and application of specific biocontrol agent for the control of diseases on plant and this form the focus of this work. Several soil bacteria were evaluated in vitro for their effectiveness on the basis of their ability to suppress fungi in plate inhibition assays. 51 strains of 12 bacterial species were performed against 12 strains of 10 phytopathogenic mould species. Almost all soil bacteria species; but about 50% of the bacteria strains, showed an antagonistic activity against at least one phytopathogenic fungus. Sphingomonans spp was the only specie that did not show any antagonistic effect to all fungi. Bradyrhizobium japonicum could highly inhibit the mycelial growth of five moulds (Botrytis cinerea, Phoma medicaginis, Fusarium verticilloides, Rhizoctonia solani and Phytophtora infestans) with a growth inhibition varying between 12.38 and 37.61%. 12 Bacillus strains and five Pseudomonas strains were antagonistic to the major phytopathogenic moulds used in this trial. Bacillus subtilis exhibited strong antagonism against fungi both from cultural medium and from sterile filtrate. Results show that bacterial suspension and bacterial supernatant did not operate in the same way. Supernatant from bacterial strains seemed to be efficient against phytopathogenic moulds. The mycelial growth of R. solani, P. medicaginis and F. verticilloides was inhibited by 12-fold dilution of the supernatant from B. japonicum. The latter draws a conclusion that bacteria isolated from soil are promising natural biocontrol agents and should be further studied and tested for the control of numerous plant diseases. Additional studies are required to definitively determine their mode of antifungal action, safety and biocompatibility.Keywords: Bacteria, phytopathogenic fungi, antagonis

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Antibody–drug conjugate; Dose-escalation study; Tusamitamab ravtansineConjugado anticuerpo-fármaco; Estudio de escalada de dosis; Tusamitamab ravtansinaConjugat anticossos-fàrmac; Estudi d'escalada de dosi; Tusamitamab ravtansinaTusamitamab ravtansine (SAR408701) is an antibody–drug conjugate composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells. In this phase I dose-escalation study, we evaluated the safety, pharmacokinetics, and preliminary antitumor activity of tusamitamab ravtansine in patients with solid tumors. Patients and methods Eligible patients were aged ≥18 years, had locally advanced/metastatic solid tumors that expressed or were likely to express CEACAM5, and had an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Patients were treated with ascending doses of tusamitamab ravtansine intravenously every 2 weeks (Q2W). The first three dose levels (5, 10, and 20 mg/m2) were evaluated using an accelerated escalation protocol, after which an adaptive Bayesian procedure was used. The primary endpoint was the incidence of dose-limiting toxicities (DLTs) during the first two cycles, graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 criteria. Results Thirty-one patients received tusamitamab ravtansine (range 5-150 mg/m2). The DLT population comprised 28 patients; DLTs (reversible grade 3 microcystic keratopathy) occurred in three of eight patients treated with tusamitamab ravtansine 120 mg/m2 and in two of three patients treated with 150 mg/m2. The maximum tolerated dose was identified as 100 mg/m2. Twenty-two patients (71%) experienced ≥1 treatment-related treatment-emergent adverse event (TEAE), seven patients (22.6%) experienced ≥1 treatment-related grade ≥3 TEAE, and three patients (9.7%) discontinued treatment due to TEAEs. The most common TEAEs were asthenia, decreased appetite, keratopathy, and nausea. Three patients had confirmed partial responses. The mean plasma exposure of tusamitamab ravtansine increased in a dose-proportional manner from 10 to 150 mg/m2. Conclusions Tusamitamab ravtansine had a favorable safety profile with reversible, dose-related keratopathy as the DLT. Based on the overall safety profile, pharmacokinetic data, and Bayesian model recommendations, the maximum tolerated dose of tusamitamab ravtansine was defined as 100 mg/m2 Q2W.This work was supported by Sanofi, France (no grant number)

GENETIC DIVERSITY OF FABA BEAN (VICIA FABA L.) POPULATIONS ESTIMATED BY ISOZYMIC AND MOLECULAR MARKERS: RELATIONSHIP BETWEEN THE TWO METHODS

In our previous studies, the genetic diversity among nine Tunisian faba bean (Vicia faba) populations was analysed using isozymes and sequence-specific amplification polymorphism (SSAP) markers. The objectives of this study were to compare the application and utility of isozymes and sequence-specific amplification polymorphism (SSAP) techniques for analysis of genetic diversity among nine Tunisian faba bean (Vicia faba) populations. A high genetic diversity within populations was detected by both isozymes (SOD, 6-PGD, ME, EST, SKDH, FDH and GDH) and (SSAP) markers (PDR1, Tps19 and Tvf4). For all populations, the genetic diversity revealed by SSAP was more pronounced than that detected with isozyme, based on polymorphic profiles. The analyses of correspondance between the tow methodes based in Mantel test revealed a low correlation ( r=0.177). The low correspondance indicated the absence of correlation and therfore the complimentarit

Epistasis and genotype-by-environment interaction of grain protein content in durum wheat

Parental, F1 , F 2 , BC 1 and BC 2 generations of four crosses involving four cultivars of durum wheat (Triticum durum Desf.) were evaluated at two sites in Tunisia. A three-parameter model was found inadequate for all cases except crosses Chili x Cocorit 71 at site Sidi Thabet and Inrat 69 x Karim at both sites. In most cases a digenic epistatic model was sufficient to explain variation in generation means. Dominance effects (h) and additive x additive epistasis (i) (when significant) were more important than additive (d) effects and other epistatic components. Considering the genotype-by-environment interaction, the non-interactive model (m, d, h, e) was found adequate. Additive variance was higher than environmental variance in three crosses at both sites. The estimated values of narrow-sense heritability were dependent upon the cross and the sites and were 0%-85%. The results indicate that appropriate choice of environment and selection in later generations would increase grain protein content in durum wheat

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

BACKGROUND: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. METHODS: This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination. Eligible patients had mesothelioma or other solid tumours with probable mitogen activated protein kinase pathway activation. Adverse events (AEs), dose-limiting toxicities, disease progression and pharmacokinetics/pharmacodynamics were analysed. RESULTS: Thirty-four subjects were enrolled. The GSK2256098/trametinib MTDs were 500 mg twice daily (BID)/0.375 mg once daily (QD) (high/low) and 250 mg BID/0.5 mg QD (low/high). The most common AEs were nausea, diarrhoea, decreased appetite, pruritus, fatigue and rash; none were grade 4. Systemic exposure to trametinib increased when co-administered with GSK2256098, versus trametinib monotherapy; GSK2256098 pharmacokinetics were unaffected by concomitant trametinib. Median progression-free survival (PFS) was 11.8 weeks (95% CI: 6.1-24.1) in subjects with mesothelioma and was longer with Merlin-negative versus Merlin-positive tumours (15.0 vs 7.3 weeks). CONCLUSIONS: Trametinib exposure increased when co-administered with GSK2256098, but not vice versa. Mesothelioma patients with loss of Merlin had longer PFS than subjects with wild-type, although support for efficacy with this combination was limited. Safety profiles were acceptable up to the MTD

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers: anaplastic thyroid carcinoma (n = 36), biliary tract cancer (n = 43), gastrointestinal stromal tumor (n = 1), adenocarcinoma of the small intestine (n = 3), low-grade glioma (n = 13), high-grade glioma (n = 45), hairy cell leukemia (n = 55) and multiple myeloma (n = 19). The primary endpoint of investigator-assessed overall response rate in these cohorts was 56%, 53%, 0%, 67%, 54%, 33%, 89% and 50%, respectively. Secondary endpoints were median duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. Median DoR was 14.4 months, 8.9 months, not reached, 7.7 months, not reached, 31.2 months, not reached and 11.1 months, respectively. Median PFS was 6.7 months, 9.0 months, not reached, not evaluable, 9.5 months, 5.5 months, not evaluable and 6.3 months, respectively. Median OS was 14.5 months, 13.5 months, not reached, 21.8 months, not evaluable, 17.6 months, not evaluable and 33.9 months, respectively. The most frequent (≥20% of patients) treatment-related adverse events were pyrexia (40.8%), fatigue (25.7%), chills (25.7%), nausea (23.8%) and rash (20.4%). The encouraging tumor-agnostic activity of dabrafenib plus trametinib suggests that this could be a promising treatment approach for some patients with BRAFV600E-mutated advanced rare cancers. ClinicalTrials.gov registration: NCT02034110

Direction Finding Antenna Arrays for the Randomly Located Source

International audienceWe consider the problem of sensor placement for estimating the direction of arrival of a narrow-band source randomly located in the far-field of a planar antenna array. Performance is evaluated by means of the expectation of the conditional Cramer Rao bound, normalized to that of the uniform circular array. Two cost functions are obtained, relative to azimuth and elevation, respectively. They depend on the array geometry as well as the distribution of the source azimuth. A class of uniform antenna arrays is investigated. It is adapted to the particular probabilistic distribution of the azimuth, while ensuring protection against array ambiguities. Using an exhaustive search procedure, we either seek the same reduction of both cost functions, or rather focus on one in particular. In the first approach, we achieve a reduction of almost 36% of both, regardless of the source azimuth distribution. In the second approach, we can obtain larger reductions for the targeted parameter. In both cases, optimal arrays are close to the V shape, for which performance analysis is conducted and closed-form expressions are obtained